Quintiles News

Please select a press release from the list below, or filter and sort to find a specific press release.

Latest Press Release

Quintiles Receives Technology Security Award from IDG's CSO Magazine for Fourth Consecutive Year

RESEARCH TRIANGLE PARK, N.C. – April 22, 2016 – Quintiles , the world’s leading provider of biopharmaceutical services, announced today that it has been named to the 2016 CSO50 by IDG's CSO magazine . This award recognizes the company’s innovative identity management solution designed to expedite activities related to the delivery of clinical trials while simultaneously protecting confidential user data. This is the company’s fourth consecutive year receiving the... Learn More
Published Date: All 2016 2015 2014 2013 2012 2011
Press Release Apr 22, 2016
RESEARCH TRIANGLE PARK, N.C. – April 22, 2016 – Quintiles, the world’s leading provider of biopharmaceutical services, announced today that it has been named to the 2016 CSO50 by IDG's CSO magazine. This award recognizes the company’s innovative identity management solution designed to expedite activities related to the delivery of clinical trials while simultaneously protecting confidential user data. This is the company’s fourth consecutive year receiving the prestigious security award. Quintiles’ Identity Management Solution introduced identity vetting, identity storage and identity synchronization that improved data quality for both existing and newly established users. The resulting system supports faster business enablement of critical project activities including site start-up...
Read More
Press Release Apr 18, 2016
RESEARCH TRIANGLE PARK, N.C. – April 18, 2016 – Quintiles Transnational Holdings Inc. (NYSE: Q) will release its first quarter 2016 financial results Tuesday, May 3, 2016 prior to its quarterly earnings call at 8:00 a.m. EDT. The conference call will be accessible, live via webcast, on the Investor Relations section of the Quintiles website at www.quintiles.com/investors. To participate via telephone, please dial +1 (855) 710-5091 in the United States or +1 (706) 902-0591 outside the United States, approximately 15 minutes before the scheduled start of the call. An archived edition of the conference call will be available online at www.quintiles.com/investors after 1:00 p.m. EDT on Tuesday, May 3rd. About Quintiles Quintiles (NYSE: Q) helps biopharma and other healthcare companies...
Read More
Press Release Mar 23, 2016
SINGAPORE – March 24, 2016 – Quintiles last night was named the “Best CRO in Asia” at the 2016 BioPharma Asia Industry Awards, winning the honor for the fourth time in the event’s six-year history.  The award goes to the contract research organization that best demonstrates an ongoing commitment to improving clinical research services in Asia and reducing lead times for customers.  “More than 1,000 votes were cast in the Best CRO category, and Quintiles was the overwhelming favorite,” said Sharon Roessen, managing director of Terrapinn Pte Ltd, organizer of BioPharma Asia Convention 2016.  “In addition to reducing lead times and advancing clinical research, Quintiles was chosen for its ability to deliver end-to-end solutions for customers and its outstanding thought leadership. Quintiles...
Read More
Press Release Mar 07, 2016
RESEARCH TRIANGLE PARK, NC – March 7, 2016 – Quintiles, the world’s largest provider of product development and integrated healthcare services, has been recognized by the Ethisphere Institute, a global leader in defining and advancing the standards of ethical business practices, as a 2016 World’s Most Ethical Company®. This year marks the tenth anniversary of Ethisphere and the World’s Most Ethical Companies designation which recognizes those companies who align principle with action, work tirelessly to make trust part of their corporate DNA, and in doing so, shape future industry standards by introducing tomorrow’s best practices today. “This award is a testament to the high standards our employees uphold every day,” said Dr. Dipti Amin, Quintiles’ Chief Compliance Officer. “Their...
Read More
Press Release Mar 04, 2016
RESEARCH TRIANGLE PARK, N.C. and CHICAGO, Ill. – March 4, 2016 – Quintiles and the American College of Surgeons (ACS) today announced a six-year strategic services agreement to improve data collection and quality reporting for all ACS clinical registries. Working together, ACS and Quintiles will build a comprehensive and integrated clinical registry platform that combines data from more than 1,800 hospitals across the United States, international medical contributors and individual surgeons to improve surgical patient care outcomes. ACS will collaborate with Quintiles to strengthen the College’s ability to improve surgical care delivery and quality by integrating six separate registries onto a common, cloud-based data platform to support quality improvement efforts and individual...
Read More
Press Release Feb 29, 2016
RESEARCH TRIANGLE PARK, N.C. – February 29, 2016 – Quintiles COO Kevin Gordon will present at the Barclays Global Healthcare Conference on Tuesday, March 15, 2016 in Miami at the Loews Miami Beach Hotel. The Quintiles presentation will begin at 1:35 p.m. (EST). Investors may access a live audio webcast of the presentation on the Quintiles’ investor relations website at www.quintiles.com/investors. An archived audio version of the presentation will be available later that day. About Quintiles Quintiles (NYSE: Q) helps biopharma and other healthcare companies improve their probability of success by connecting insights from our deep scientific, therapeutic and analytics expertise with superior delivery for better outcomes. From advisory through operations, Quintiles is the world’s largest...
Read More
Press Release Feb 22, 2016
RESEARCH TRIANGLE PARK, N.C. – February 22, 2016 – Quintiles, the world’s largest biopharmaceutical services company, has been named to Fortune magazine’s “World’s Most Admired Companies” list for 2016, the second year in a row for this distinction. Quintiles is ranked first overall in Fortune’s Healthcare: Pharmacy and Other Services industry category, up from number three in 2015. Also within its industry category, Quintiles was ranked first or second across all nine “key attributes” which Fortune survey respondents use in evaluating nominated companies. The company was ranked first in the categories of: Quality of Products / Services Global Competitiveness Long-term Investment Social Responsibility Fortune's “World's Most Admired Companies” list is the definitive...
Read More
Press Release Feb 17, 2016
RESEARCH TRIANGLE PARK, N.C. – February 17, 2015 – Quintiles CEO Tom Pike will present at the Raymond James & Associates 37th Annual Institutional Investors Conference on Monday, March 7, 2016 in Orlando, Florida at the JW Marriott Grande Lakes resort. The Quintiles presentation will begin at 2:50 p.m. (EST). Investors may access a live audio webcast of the presentation on the Quintiles’ investor relations website at www.quintiles.com/investors. An archived audio version of the presentation will be available later that day. About Quintiles  Quintiles (NYSE: Q) helps biopharma and other healthcare companies improve their probability of success by connecting insights from our deep scientific, therapeutic and analytics expertise with superior delivery for better outcomes. From advisory...
Read More
Press Release Feb 11, 2016
Research Triangle Park, NC, February 11, 2016 – Quintiles Transnational Holdings Inc. (“Quintiles” or the “Company”) (NYSE: Q) today reported its financial results for the quarter and year ended December 31, 2015. 9.4% constant currency service revenue growth compared to the fourth quarter of 2014 $0.90 diluted adjusted EPS representing 26.8% growth compared to the fourth quarter of 2014, fourth quarter GAAP reported diluted EPS of $0.85 Net new business of $1.49 billion in the fourth quarter of 2015, representing a 1.32 book-to-bill ratio and increasing backlog to $12.04 billion as of December 31, 2015 $265 million of share repurchases during the fourth quarter of 2015 Full year 2016 service revenue guidance of 7.0% to 8.5% constant currency growth compared to full...
Read More
Press Release Feb 05, 2016
RESEARCH TRIANGLE PARK, N.C. – February 5, 2016 – Quintiles, the world’s largest biopharmaceutical services company, has been awarded the HR.com 2016 Leadership Excellence Award for Innovation in Deployment of Leadership Programs.    HR.com, the largest global social networking and resource site for HR professionals, is committed to providing a deeper understanding of the HR function for over 250,000 members. For more than 33 years, they have identified and recognized the top organizations that develop their leaders. This year’s awards had more than 4,500 companies apply with 600,000 people voting on their programs to provide the most comprehensive ratings ever produced. These prestigious leadership awards salute the world’s best leadership practitioners and highlight their roles in the...
Read More
Press Release Jan 18, 2016
RESEARCH TRIANGLE PARK, N.C.-- Quintiles Transnational Holdings Inc. (NYSE: Q) will release its fourth-quarter 2015 financial results Thursday, February 11, 2016 prior to its quarterly earnings call at 8:00 a.m. EST. The conference call will be accessible, live via webcast, on the Investor Relations section of the Quintiles website at www.quintiles.com/investors. To participate via telephone, please dial +1 (855) 710-5091 in the United States or +1 (706) 902-0591 outside the United States, approximately 15 minutes before the scheduled start of the call. An archived edition of the conference call will be available online at www.quintiles.com/investors after 1:00 p.m. EST on Thursday, February 11th. About Quintiles Quintiles (NYSE: Q) helps biopharma and other healthcare companies...
Read More
Press Release Dec 21, 2015
RESEARCH TRIANGLE PARK, N.C. – December 21, 2015 – Quintiles CEO Tom Pike will present at the 34th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2016 in San Francisco at the Westin St. Francis Hotel. The Quintiles presentation will begin at 3:30 p.m. (PST).  Investors may access a live audio webcast of the presentation on the Quintiles’ investor relations website at www.quintiles.com/investors.  An archived audio version of the presentation will be available later that day. About Quintiles Quintiles (NYSE: Q) helps biopharma and other healthcare companies improve their probability of success by connecting insights from our deep scientific, therapeutic and analytics expertise with superior delivery for better outcomes.  From advisory through operations, Quintiles is...
Read More
Press Release Dec 10, 2015
RESEARCH TRIANGLE PARK, N.C. – December 10, 2015 – Quintiles, the world’s largest provider of biopharmaceutical services, today announced the launch of its Integrated Asset Development Plan (IADP) offering. This new suite of services combines development strategy, regulatory strategy, market and patient access and commercial expertise, with in-depth therapeutic knowledge, a facilitated strategic-planning process, data analytics and modeling to deliver an integrated asset-development plan. IADP brings together cross-functional strategies and operational delivery to enable more informed decisions that speed market access, fulfill regulatory requirements and help optimize commercial potential. Potential assets that could benefit from this new offering include small molecule drugs,...
Read More
Press Release Nov 09, 2015
RESEARCH TRIANGLE PARK, N.C. – November 9, 2015 – Quintiles, the world’s largest biopharma services provider, has announced its contribution of enhancements to the ResearchKit framework which was designed by Apple to make it easy for researchers to gather data more frequently and more accurately from research participants using iPhone apps. ResearchKit enables participants to easily complete tasks or submit surveys right from an app and delivers a simple way to present participants with an interactive informed consent process. Quintiles contributed enhancements to the ResearchKit framework to provide developers with extensions that support additional capabilities which, in turn, will allow them to create more sophisticated application experiences. Quintiles plans to use these...
Read More
Press Release Nov 05, 2015
RESEARCH TRIANGLE PARK, N.C. – November 5, 2015 – Today, the Quintiles Transnational Holdings Inc. (the “Company”) Board of Directors increased the Company’s share repurchase authorization by $300 million for repurchase of the Company’s outstanding common stock. The share repurchase program does not obligate the Company to acquire any particular amount of common stock, has no end date, and may be modified, suspended, or discontinued at any time. The timing and amount of repurchases are determined by the Company’s management based on a variety of factors such as the market price of the Company’s common stock, the Company’s corporate requirements, and overall market conditions. Purchases of the Company’s common stock may be made in open market transactions effected through a broker-dealer...
Read More
Press Release Nov 05, 2015
RESEARCH TRIANGLE PARK, N.C.– November 5, 2015 – Quintiles Founder Dr. Dennis Gillings, CBE, will retire from his position as Executive Chairman of Quintiles Transnational Holdings Inc. (NYSE: Q) at the end of this year, December 31, 2015. Dr. Gillings will remain on the Board as a director. The Board has appointed Jack M. Greenberg to serve as Chairman of the Board, effective January 1, 2016.  Dr. Gillings began performing biostatical analysis work for pharmaceutical companies with a single project in 1974 while still a professor of biostatistics at the University of North Carolina at Chapel Hill. That small consulting business, which would become Quintiles, began with a handful of staff working out of a trailer on the UNC campus. Quintiles was incorporated as a privately held company...
Read More
Press Release Nov 03, 2015
RESEARCH TRIANGLE PARK, NC - Quintiles CEO Tom Pike will present at the Credit Suisse 2015 Healthcare Conference on Tuesday, November 10, 2015 in Phoenix at the Phoenician resort. The Quintiles presentation will begin at 10:30 a.m. (MST). Investors may access a live audio webcast of the presentation on the Quintiles’ investor relations website at www.quintiles.com/investors. An archived audio version of the presentation will be available later that day. About Quintiles Quintiles (NYSE: Q) helps biopharma and other healthcare companies improve their probability of success by connecting insights from our deep scientific, therapeutic and analytics expertise with superior delivery for better outcomes. From advisory through operations, Quintiles is the world’s largest provider of product...
Read More
Press Release Oct 30, 2015
RESEARCH TRIANGLE PARK, N.C. – October 30, 2015 – Quintiles, the world’s largest provider of product development and integrated healthcare services, today published new research that reveals high levels of patient satisfaction and engagement in clinical research. Based on a survey of U.S. clinical research patients, all of the respondents agreed that clinical research participation reduced their overall cost of healthcare and improved their interest/involvement in their overall health. In addition, 95 percent of survey participants said that participating in clinical research positively impacted their overall quality of care. “These findings illustrate the value of integrating clinical research into the traditional continuum of care,” said Jeanne Hecht, senior vice president, Site &...
Read More
Press Release Oct 28, 2015
Research Triangle Park, NC, October 28, 2015 – Quintiles Transnational Holdings Inc. (“Quintiles” or the “Company”) (NYSE: Q) today reported its financial results for the quarter ended September 30, 2015. 8.3% constant currency service revenue growth compared to the third quarter of 2014 44.6% increase in diluted adjusted EPS to $0.94 per share compared to the third quarter of 2014, third quarter GAAP reported diluted EPS of $0.89 Net new business of $1.16 billion, increasing backlog to $11.75 billion as of September 30, 2015 Updating full year 2015 constant currency service revenue growth guidance to a range of 8.6% - 9.2% compared to full year 2014 and increasing diluted adjusted EPS guidance to $3.27 - $3.33 per share, representing diluted adjusted EPS growth of 21.1%...
Read More
Press Release Oct 22, 2015
RESEARCH TRIANGLE PARK, NC and DANBURY, CT, October 22, 2015 – Quintiles and IMS Health today announced a global strategic alliance that will advance the way biopharmaceutical companies generate real-world evidence (RWE) and apply critical insights to drive late-stage clinical research. With complementary strengths in real-world data management, operational delivery, advanced analytics, and scientific and therapeutic expertise, the collaboration will accelerate assessments of treatment impact and help improve patient outcomes. As healthcare stakeholders increase their focus on value, evidence of a medicine’s effectiveness and safety in real-world settings continues to be a critical component of drug development and healthcare delivery. This alliance brings together market-leading...
Read More